Antivirals / Internal Use

Rimantadine 0.05g (20 tablets)

Brands: Biosintez (Russia)

$2.90

Quantity

Rimantadine 0.05g (20 tablets) quantity

Add to cart

Add to wishlist

Sku:

7a585cd493bc

Brands:: Biosintez (Russia)

Description

The instruction for medical use of medicine Rimantadinum the Trade name Rimantadinum the International unlicensed name Rimantadinum Dosage Form of the Tablet of 0.05 g Structure One tablet contains active agent – Rimantadinum a hydrochloride – 0.050 g, excipients: lactoses monohydrate (sugar milk), potato starch, talc, calcium stearate the Description of the Tablet of white color, a ploskotsilindrichesky form with a facet. Pharmacotherapeutic group Antiviral drugs for system use. Antiviral drugs of direct action. Cyclic amines. Rimantadinum the ATX J05AC02 Code the Pharmacological Pharmacokinetics Later properties of intake Rimantadinum is almost completely soaked up in intestines. Absorption is slow. Communication with proteins of plasma – about 40%. Distribution volume: adult – 17-25 l/kg, children – 289 l/kg. Concentration in a nasal secret is 50% higher, than in plasma. The maximum concentration of active ingredient in blood plasma at a dose of 100 mg once a day – 181 ng/ml, on 100 mg 2 times a day – 416 ng/ml. It is metabolized in a liver. Elimination half-life – 24 – 36 hours, 75 – 85% of the accepted dose is removed by kidneys generally in the form of metabolites, 15% – in an invariable look. In chronic kidney disease the elimination half-life increases twice. At persons with a renal failure and at elderly people can collect in toxic concentration if the dose is not adjusted in proportion to reduction of clearance of creatinine. A pharmacodynamics Rimantadinum is active concerning various influenza strains of A. Yavlyayas the weak basis, Rimantadinum works due to increase rn the endosomes having a membrane of vacuoles which surround virus particles after their penetration into a cell. Prevention of an atsidifikation in these vacuoles blocks merge of a viral envelope to an endosome membrane, preventing thus transfer of virus genetic material to cell cytoplasm. Rimantadinum oppresses also an exit of virus particles from a cell, that is interrupts a transcription of a virus genome. Indications – prevention and early treatment of flu A at adults and children are more senior than 7 years the Route of administration and doses Inside, after a meal, washing down with water. Treatment of flu should be begun within 24 – 48 hours after emergence of symptoms of a disease. The adult in the first day appoint 100 mg (2 tablets on 50 mg) 3 times a day, in the second and third days on 100 mg 2 times a day, in the fourth and fifth day on 100 mg once a day. In the first day of a disease the drug use once in a dose of 300 mg is possible (6 tablets on 50 mg). To children aged from 7 up to 10 years appoint 50 mg 2 times a day, from 11 to 14 years – 50 mg 3 times a day. 14 years – doses for adults are more senior. Accept within 5 days. For prevention of flu adult appoint 50 mg lasting up to 30 days once a day. To children 7 years – 50 mg once a day within 15 days are more senior. Side effects – dryness in a mouth, nausea, vomiting, loss of appetite, pain in epigastriums, a meteorism – a headache, dizziness, insomnia, disturbance of concentration of attention, drowsiness, uneasiness, hyperexcitability, fatigue – a hyperbilirubinemia – allergic reactions (skin rash, an itching, a small tortoiseshell) of the Contraindication – hypersensitivity to Rimantadinum and auxiliary components of drug – acute diseases of a liver – acute and chronic diseases of kidneys – a thyrotoxicosis – pregnancy and the period of a lactation – children’s age up to 7 years – a lactose intolerance, a lactose intolerance, glyukozo-galaktozny malabsorption With care – arterial hypertension – atherosclerosis of vessels of a brain – a liver failure – epilepsy – digestive tract diseases Medicinal interactions Rimantadinum reduces efficiency of antiepileptic drugs. Paracetamol and ascorbic acid reduce the maximum concentration of Rimantadinum in blood plasma by 11%. Cimetidinum reduces clearance of Rimantadinum by 18%. The adsorbents knitting and enveloping means reduce Rimantadinum absorption. The means alkalinizing urine (acetazoleamide, Natrii hydrocarbonas and others) enhance efficiency of Rimantadinum owing to reduction of its removal by kidneys. Special instructions At use of Rimantadinum the exacerbation of chronic associated diseases is possible. At patients of advanced age with arterial hypertension the risk of developing a hemorrhagic stroke increases. At instructions in the anamnesis on epilepsy and the carried-out anticonvulsant therapy against the background of use of Rimantadinum the risk of developing an epileptic seizure increases. In such cases Rimantadinum apply in a dose 100 mg a day along with anticonvulsant therapy. Preventive reception is effective at contacts with the diseased, at spread of an infection in the closed collectives and at high risk of developing of a disease during a flu epidemic. Appearance of viruses, resistant to drug, is possible. Pregnancy and the period of a lactation Drug is contraindicated during pregnancy and in the period of a lactation. The feature of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms during use needs to refrain from control of transport and occupations other potentially dangerous types of activity demanding the increased concentration of attention and speed of psychomotor reactions. Overdose Symptoms: excitement, hallucinations, arrhythmia. Treatment: gastric lavage, symptomatic therapy: actions for maintenance of the vital functions. Rimantadinum is partially removed at a hemodialysis. The form of release and packing On 20 tablets place in banks polymeric the BP type. Each can together with the instruction for medical use in the state and Russian languages is placed in a pack from cardboard. To Store storage conditions in the dry place at a temperature not above 25 °C. To store out of children’s reach! Not to use a period of storage of 5 years after an expiration date. Prescription status Without prescription JSC Biosintez Producer, Russia 440033, Penza, Druzhby St., 4, ph./fax (8412) 57-72-49, e-mail: certificate@biosintez.com the Owner of the registration certificate of JSC Biosintez, Russia the Address of the organization accepting in the territory of the Republic of Kazakhstan claims from consumers on quality of the products (goods) responsible for post-registration observation of safety of medicine of JSC Biosintez, Russia 440033, Penza, Druzhby St., 4, ph./fax (8412) 57-72-49, e-mail: certificate@biosintez.com

Additional information